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Chronic arsenical intoxication can still be found in environmental and industrial settings.
Symptoms ofchronic arenic intoxication indude general pigmentation or focal raindrop' pig-
mentation oftheslin andthe ap ce ofheeratois ofthepalms ofthehands and solesof
the feet. In addition to arenic-relted skin disea including keratosi, Bowen's dies, basal-
cell-carcinoma, and squamous-cell carcinoma, there is also an incese risk of some internal
malignancies. Arsenic-related diseases are common in areas oftheworldwhere theddnking water
has ahigharsenic content. Inthis paper, wedescribe a35-year-old male patientwho had arsenic-
related keratosis, squamouscl arcoma in the palmararea of.his left hand, and Bowen's dis-
ease on his left thigh. The patient worked in a borax mine for 15 years, so he was exod to
arsenic in drinking water, airborne arsenic in hisworkplace, and had direct contact. The patient
was treated for 11 months for asic-related keratosis until an azilay lymph node metastasis
occurred; the lesion was excised and diagnosed to be m nt Bowen's disease wa detected
when the patient was being treated for cancer. No other malignancy was found. The patient is
st receiving regula follow-up care. Key awon&arseic, Bowen's disease, katosis, skin cancer.
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Case Presentation
A35-year-old male patientwith a hyperkera-
totic lesion on the palm ofhis left hand was
admitted to the SSK Ktitahya Hospital 5
years ago. The patient had a history of
fatigue, weakness, and weight loss, but no
complaints related to the gastrointestinal
tract or other systems.
The lesion, located in the palmar area of
his left hand, was diagnosed to be arsenic-
related keratosis (Figure 1), and treatment
with topical medications was initiated.
The patient had been working as a col-
manit and arsenic mine cleaner and separa-
tor in the Emet-Hisarcik borax mine for 15
years, where he received intense borax and
arsenic exposure. This borax mine is located
in the western part ofTurkey and is owned
by the government. There is a high arsenic
content in the product of the mine-cole-
manit. Workers are required to wear gloves,
but this patient did not wear gloves and did
not use a mask to prevent arsenic exposure
because ofhis inadequate knowledge.
The patient was shifted to another posi-
tion at work to prevent further direct expo-
sure to arsenic. However, because he lived in
the same region, his exposure to arsenic con-
tinued. There was still a high level ofarsenic
both in theworkplace and in hometap water.
One year after the initial diagnosis, left
axillary lymphadenopathy was found, and a
biopsy of the left axillary lymph node was
performed in The Ankara University fbn-i
Sina Hospital. Histopathologic examination
revealed metastasis of a squamous-cell carci-
noma (SCC) to the lymph node. The palmar
lesion was biopsied again, with the primary
focus on axillary malignant disease, but no
malignancy was found. A left axillary lym-
phadenectomy was performed afterward,
and all lymph nodes were free of malignan-
cy. A combination of chemotherapy with
cysplatin and 5-fluorouracil (5-FU) and
radiotherapy (total dose of 6,000 cGy) was
then administered to the patient. At the 6-
month follow-up, the patient was diagnosed
with a new hyperkeratotic lesion on his left
thigh, which had been present for 5 months
(Figure 2). The patient was then seen by the
Epidemiology Study Group of Ankara
University, School ofMedicine, who were in
the area to perform epidemiologic screening.
The patient was evaluated regarding acute
and chronic arsenic intoxication.
The patient had weakness and fatigue,
and had lost 5 kg of body weight over the
previous 2 years, but he had no gastro-
intestinal complaints (nausea, vomiting, or
diarrhea). Computed tomography and
ultrasonography of the abdomen were nor-
mal. No pathological findings were revealed
by neurological examination or electromyog-
raphyofthe patient. Additionally, no abnor-
malities were found in urinary examination
or cystoscopy. The results of the laboratory
tests are presented in Table 1.
Multiple biopsies were made from the
lesions on the palm and the thigh. The pal-
mar lesion was determined to be arsenic-
related keratosis, whereas the lesion on the
thigh was found to be pagetoid Bowen's dis-
ease. We performed a systemic search for
internal malignancy using physical, hemato-
logical, biochemical, and radiological tests.
We excised all lesions, including a mar-
gin of 2 cm of normal skin. The wounds
were closed with full-thickness skin grafts.
Findings ofthe histopathologic examination
of the palmar lesion included large and
hyperchromatic nucleated epithelial cells
with atypical mitosis and evident nucleoli,
tumor cells with globes, and spindle nucle-
oli. The basal membrane was intact, in gen-
eral, but a focal invasion was noted. The
palmar lesion was determined to be a well-
differentiated (spindle-cell) SCC, whereas the
lesions on the thigh were accepted to be
Bowen's disease with high grade dysplasia.
There were no complications in the postoper-
ative period, and the patient was discharged.
He was monitored in the first month afterthe
surgeryand no abnormalitywas found.
Discussion
Arsenic is a metal used extensively in the
makingofglass, alloys, coloringagents, insec-
ticides, and fungicides. Currently, arsenic is
employed in metallurgy, agriculture, animal
husbandry, and forestry; it is widely distrib-
uted in nature, being mainly transported by
water in the environment. The industrial
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applications ofarsenic account for the major-
ity of use of inorganic and organic arsenic
compounds. In an occupational setting, the
respiratory tract provides the most common
portal ofentry for arsenic. Skin and gastroin-
testinal pathways are also possible (1).
Our patient was exposed to arsenic
exposure by ingestion (drinking water, and
foods) and by direct contact with colemanit.
The drinking water in the area where the
patient lived and worked contained 405
,ug/L arsenic, with a range of 45-1,210
pg/L. Colemanit (2CaO * 3B203 * 5H2O),
the mineral that the patient continuously
handled for 15 years, contained 50.9%
B20, 21.9% H2O, 27.2% CaO, and 1,000
ppm (1 g/kg) arsenic. Fifteen years of high
arsenic exposure at work may have caused
arsenic-related skin cancer.
The current standard of the U.S.
Environmental Protection Agency (U.S.
EPA) for inorganic arsenic in drinking
water is 50 ppb (micrograms per liter);
the Occupational Safety and Health
Administration (OSHA) established a maxi-
mum permissible exposure limit (PEL) for
workplace airborne arsenic: 10 pg/m3 (1).
Current U.S. EPA risk analyses predict that
beyond the concentration of 50 ppb arsenic
in drinking water, lifetime skin cancer risk
would increase by 3 or 4 per 1,000 (2).
Arsenic poisoning is usually the result of
accidental or homicidal ingestion of insecti-
cides or rodenticides containing copper ace-
toarsenate, calcium arsenate, or lead arsenate.
Arsenic trioxide, the most dangerous form of
arsenic, is still used in chemistry laboratories
and a few industries. This is a soluble powder
with an acute lethal dose in humans of
60-120 mg (3). Arsenic reacts with the
sulfhydryl groups in certain tissue proteins
and thus interferes with a number ofenzyme
systems essential to cellular metabolism.
Pathologic changes in fatal inorganic arsenical
poisoning are fatty degeneration of the liver,
hyperemia and intestinal hemorrhages, and
renal tubuler necrosis. The peripheral nerves
often show fragmentation and resorption of
myelin, with disintegration of axis cylinders.
Gastrointestinal symptoms develop after acute
ingestion, followed by a mixed motor and
sensory neuropathy after 2-3 weeks. Tendon
reflexes are absent or diminished, and atrophy
of affected muscles develops rapidly. The
patients who present with arsenic poisoning
do not have neurological complaints or find-
ings. The symptoms of acute poisoning by
oral exposure are vomiting, diarrhea, weak-
ness, prostration, and weight loss (4). Patients
who recover from acute poisoning and those
with chronic intoxication usually develop skin
and mucosal changes, peripheral neurological
symptoms, and typical pigmentations in the
nails. The cutaneous manifestations appear
within 1-4 weeks and consist ofadiffuse, dry,
scaly desquamation, occasionally with hyper-
pigmentation, over the trunk and extremities.
Hyperkeratoses of the soles of the feet and
edema of the face and extremities may also
occur. The mucous membranes also show
evidence of irritation, for example, conjunc-
tivitis, photophobia, pharyngitis, or irritating
cough. About 5 weeks after
exposure to arsenic, a trans-
verse white stria, 1-2 mm in
width, appears above the
lunula of each fingernail
(Mees lines). Our patient I'
had a hyperkeratotic lesion




convulsions are seen in both -
acute and chronic intoxica-
tion. The extremities show a
decrease in sensitivity to touch, pain, and
temperature sensation, with a symmetrical
"stocking-glove" distribution; distal weak-
ness ofgrip; and wrist drop.
Our patient suffered from weakness,
fatigue, and loss of weight, but he had no
gastrointestinal complaints. Computed
tomography and ultrasonography of the
abdomen were normal.
The laboratory findings of acute arsenic
poisoning usually consist of moderate ane-
mia and a leukopenia of 2,000-5,000 white
blood cells with mild eosinophilia. There is
slight proteinuria, and liver function tests
show mild abnormalities. Our patient did
not have leukopenia, eosinophilia. or pro-
teinuria, and his liver function tests were
normal. In urinary examination and cys-
toscopy, no abnormalities were found. None
ofthe clinical or laboratory manifestations of
arsenic poisoning are specific, and the diag-
nosis depends on analysis of the hair and
urine for arsenic. A normal person has an
average concentration of0.05 mg arsenic per
100 mg hair, with a range of 0.025-0.088
mg. Concentrations ofarsenic > 0.1 mg/100
mg hair indicate arsenic poisoning.
Because we do not have the facilities to
analyze the samples in our laboratories, we
Figure 1. Arsenic related skin cancer on the palmar area of the left hand. Figure 2. Bowen's disease on the leftthigh.
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were unable to determine the arsenic levels
in serum, tissue, and urine.
It is difficult to establish the minimal
level ofarsenic in urine indicating intoxica-
tion. Normal persons have been found to
excrete between 0.01 and 0.06 mg arsenic/L
of urine. Collection of urine for arsenic
analysis should be performed after abstain-
ing from eating seafood, which contains
arsenobentaine (which is relatively harm-
less). Although there is considerable overlap,
most patients with evidence of arsenic
intoxication excrete > 0.1 mg/L; soon after
acute exposure, many show concentrations
> 1 mg/L (4).
The relationship of arsenic ingestion to
palmar and plantar keratoses and to skin can-
cer has been documented in studies involving
wide-scale exposure to known sources of
arsenic (5-8). The strongest epidemiologic
evidence on the effects ofarsenic on the skin
was reported in a Taiwanese study performed
in an areawith high arsenic concentrations in
wellwater (5,6). Jaafaretal. (i) reported three
cases ofskin cancer caused by arsenic poison-
ing in patients who had lived near tin mines
in Malaysia. In Slovakia, skin cancers were
reported to be common in areas pollutedwith
arsenic (8). Arsenic-related Bowen's disease
has predominantly been found in agricultural
workers who use arsenical powders in crop
dustingand wine growing (). Malignant and
premalignant skin lesions have been reported
among paraquat manufacturing workers
(10,11). Studies have demonstrated a signifi-
cant dose-response relationship with the
duration ofexposure (11,12).
Inorganic arsenic is a carcinogenic agent
for the respiratory system, skin, liver, and
bladder. In epidemiologic studies in different
countries, a positive association between






Erythrocyte sedimentation rate 40 mm/hr
White blood cell count 4.5 x 103
Platelet count 218 x 103
Glucose 111 mg/dL
Blood urea nitrogen 20 mg/dL
Creatinine 1.4 mg/dL
Uric acid 10 mg/dL
Calcium 10.3 mg/dL
Inorganic phosphorus 5 mg/dL
Albumin 4g/dL
Total bilirubin 0.7 mg/dL
Aspartate aminotransferase 29 U/L
Alanine amino transferase 39 U/L
Lactic dehydrogenase 180 U/L
Alkaline phosphatase 245 U/L
Carsino embriogenic antigene 2.7 ng/mL
CA 15-3 23.6 U/mL
Inorganic arsenic compounds in drink-
ing water, exposure in the workplace, and
drug therapy with inorganic arsenicals have
been causally related to the development of
skin cancer. Smelter employees and other
workers exposed to arsenic trioxide have
been shown to have a gready increased risk
oflung cancer (3). Increased mortality from
bronchial carcinoma has been found in
chemical workers in the production ofinor-
ganic arsenicals. Exposure in the past has
been heavy and has been predominantly to
arsenic trioxide; in smelter workers, exposure
patterns are mixed, and other suspected car-
cinogens are frequently present. Data from
other than occupational sources support the
carcinogenic role ofarsenic for lung cancer,
bladder cancer, and liver angiosarcoma (14).
The site of lesions was also typical for
arsenic-related skin cancer. Arsenic exposure
is a well-known cause ofskin cancer, but for
this case, we believe that chronic and direct
contact ofarsenic with the skin at the site of
lesion should beoverlooked.
Malignant transformation of arsenic-
related keratosis is quite rare. In this case,
either a malignant transformation of
arsenic-related keratosis or synchronous ini-
tiation of both diseases may be possible.
Bowen's disease is an intraepidermal SCC of
the skin or mucous membrane that pursues
a slow and relatively benign course (hori-
zontal or intraepidermal growth) over a
period ofyears, but may progress to invasive
SCC (vertical growth). Arsenic, ultraviolet
light (UV), radiation, psoralen, and pso-
ralen plus UV light of A wavelength
(PUVA) may have a role in the etiology of
Bowen's disease (15-17). In Bowen's dis-
ease, lesions may be found in areas of the
skin and mucous membranes including the
nailbeds, palms, and soles. Individual lesions
ofBowen's disease tend to persist for many
years without progression to invasive carci-
noma. If untreated, 5-15% will present
invasion and/or metastasis. Statistical stud-
ies do not support a relationship between
Bowen's disease and internal cancers (18).
The relationships among arsenic exposure,
punctuate keratoses, and internal malignan-
cies are less documented, although highly
suggestive (19). Subsequent reports did not
support that palmar and plantar keratoses
could be markers of systemic cancer
(20,21). In our patient, no primary focus
for internal malignancywas detected.
In conclusion, the presented case is an
important example ofarsenic-related skin dis-
ease. One should always be concerned about
malignancy in such cases. Although it is yet
unproven, direct contact with arsenic may be
hazardous and should be avoided. Presence
of arsenic in the environment (water, food,
etc.) should be closely monitored. For this
purpose, an epidemiologic study to deter-
mine the effects of arsenic and borax on
public and environmental health has been
initiated by the Public Health Department
ofAnkara University Medical School in
Turkey; Turkey is the greatest borax producer
in theworld after the United States.
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